Treatment
Dapagliflozin clinical trials
We’re tracking 85 recruiting studies that include Dapagliflozin, each written for real people, not researchers, below.
Recruiting studies
- NCT07662109RecruitingPhase 3
Testing a new combo pill for type 2 diabetes
This study tests if a new medicine (elecoglipron) combined with dapagliflozin is safe and works better for adults with type 2 diabetes that isn't well controlled by diet or other medications.
Huntsville, AlabamaAges 18 years+ - NCT07662044RecruitingPhase 3
Studying elecoglipron for type 2 diabetes
This trial tests a new medicine called elecoglipron, taken alone or with another diabetes drug (dapagliflozin), to see if it helps control blood sugar better than a placebo. It may be an option if your current treatment isn't working well enough.
Birmingham, AlabamaAges 18 years+ - NCT07482943RecruitingPhase 4
Dapagliflozin for heart function after Fontan procedure
This trial tests whether dapagliflozin, a diabetes drug that also helps the heart, can improve exercise ability and heart function in people who have had the Fontan procedure for a single ventricle heart defect.
Hong KongAges 12 years+ - NCT07025629RecruitingPhase 3
Dapagliflozin after ICU discharge for heart and kidney health
This study tests if the drug dapagliflozin (a medicine that helps protect the heart and kidneys) can improve recovery in patients who needed a breathing machine or blood pressure support in the ICU. If you qualify, you would take the drug after leaving the ICU to see if it lowers the risk of heart or kidney problems.
ParisAges 18 years+ - NCT06890143RecruitingPhase 3
Dapagliflozin for kids with genetic kidney disease and protein in urine
This trial tests if dapagliflozin, a medication that lowers blood sugar and protects the kidneys, can reduce protein in the urine of children with inherited kidney disease. It may help preserve kidney function when added to standard blood pressure medication.
Shanghai, Shanghai MunicipalityAges 6–18 - NCT06677060RecruitingPhase 3
Study of baxdrostat plus dapagliflozin for heart risk in type 2 diabetes
This study tests whether a new drug called baxdrostat, when added to the diabetes medicine dapagliflozin (Farxiga), can prevent heart failure and heart-related death in people with type 2 diabetes, high blood pressure, and existing heart or blood vessel disease. You may be able to join if you have type 2 diabetes, heart or blood vessel disease, high blood pressure, and at least one extra risk factor for heart failure.
Birmingham, AlabamaAges 40 years+ - NCT06307652RecruitingPhase 3
Testing a new heart failure and kidney treatment combo
This study tests a new combination of two medicines (balcinrenone and dapagliflozin) for people with heart failure and reduced kidney function. The goal is to see if this combination helps improve heart and kidney health better than current treatments.
Alexander City, AlabamaAges 18–130 - NCT06398977Recruiting
Dapagliflozin to protect kidney function in dialysis patients
This trial tests whether a diabetes drug called dapagliflozin can help people on peritoneal dialysis keep their remaining kidney function longer. It is for patients who started dialysis recently and still make urine.
Chengdu, SichuanAges 18–75 - NCT07684326RecruitingPhase 2/Phase 3
Can dapagliflozin help liver cirrhosis with fluid buildup? (Phase 2/3 randomized trial)
This trial tests a diabetes pill (dapagliflozin) to see if it helps people with liver cirrhosis and fluid buildup (ascites). The goal is to improve fluid balance and possibly reduce hospital stays.
GizaAges 18 years+ - NCT07624305RecruitingPhase 3
Balcinrenone and Dapagliflozin for Moderate-to-Severe Kidney Disease
This study tests a combination of two medications (balcinrenone and dapagliflozin) to help protect your kidneys if you have moderate-to-severe chronic kidney disease. The trial evaluates whether this combination slows kidney damage and improves kidney health.
Huntsville, AlabamaAges 18–99 - NCT06304857RecruitingPhase 3
Protecting the heart with dapagliflozin during breast cancer treatment
This trial tests if the diabetes drug dapagliflozin can protect the heart in people with breast cancer receiving a type of chemotherapy called anthracyclines. You may be able to join if you are between 18 and 80, have stage I-III breast cancer, and are about to start anthracycline treatment within the next 60 days.
Wroclaw, Lower Silesian VoivodeshipAges 18–80 - NCT05944016RecruitingPhase 3
Dapagliflozin for early Alport kidney disease in teens and young adults
This trial tests dapagliflozin, a daily medicine, to slow kidney problems in people with early-stage chronic kidney disease caused by Alport syndrome. It may help protect kidney function and reduce worsening over time.
Heidelberg, Baden-WürttenbergAges 10–39 - NCT07515391Enrolling by invitationPhase 2
Blood Sugar Control After Weight-Loss Surgery
This trial tests whether a diabetes medication called dapagliflozin helps smooth out blood sugar swings after bariatric (weight-loss) surgery. It may help people with type 2 diabetes achieve better control after their surgery.
Kuwait City, DasmanAges 21–70 - NCT06783166RecruitingPhase 2/Phase 3
Comparing two medications for acute heart failure with fluid buildup
This trial tests if dapagliflozin or acetazolamide works better for people hospitalized with heart failure who have extra fluid in their body (congestion). The study will compare how well each medication helps remove fluid when used with standard IV diuretics.
Al MansurahAges 18 years+ - NCT05359263RecruitingPhase 2
Dapagliflozin for kidney disease to improve heart structure
This Phase 2 study tests whether dapagliflozin can improve heart structure and function in people with chronic kidney disease (CKD). Dapagliflozin is a kidney-heart medicine that may affect how the heart changes over time, measured by heart scans.
CopenhagenAges 18 years+ - NCT07323524RecruitingPhase 4
Dapagliflozin for active lupus kidney disease
This study tests if a diabetes drug called dapagliflozin can help people with active lupus nephritis by reducing protein in the urine and preserving kidney function. It is given in addition to standard treatments.
Boston, MassachusettsAges 18–70 - NCT05788276RecruitingPhase 4
Dapagliflozin to help transplanted kidneys stay healthy
This study tests whether dapagliflozin can preserve the structure and function of a kidney transplant. You may be asked to take dapagliflozin on top of usual transplant medicines to see if it helps the new kidney work better over time.
Oslo, OsloAges 18–75 - NCT07245069RecruitingPhase 2
Can dapagliflozin protect the heart during breast cancer chemo?
This trial tests if the drug dapagliflozin can prevent heart damage caused by anthracycline chemotherapy in breast cancer patients. It aims to see if taking the drug during chemo helps keep your heart healthy.
LjubljanaAges 18 years+ - NCT06897605RecruitingPhase 2
Dapagliflozin for anemia in kidney disease
This trial tests whether a medication called dapagliflozin can help improve anemia in people with chronic kidney disease. If you have moderate to severe kidney disease and low red blood cell counts despite taking standard anemia treatment, this study may explore a new option.
Al MansurahAges 18 years+ - NCT07239011RecruitingPhase 1/Phase 2
Dapagliflozin for depression study
This trial tests whether dapagliflozin, a diabetes medication, can help treat major depression. It is for adults who have been depressed for at least 2 months and score high on a depression scale.
Damietta, New DamiettaAges 18–60 - NCT07235280RecruitingEarly Phase 1
Testing dapagliflozin before surgery for early stage lung cancer
This trial tests the safety of dapagliflozin (a diabetes drug) taken before surgery for stage IA lung adenocarcinoma. It may help understand if this drug can slow tumor growth while waiting for surgery.
Los Angeles, CaliforniaAges 22 years+ - NCT06286878RecruitingPhase 2/Phase 3
Dapagliflozin after a heart attack: recovery study
This trial tests whether a diabetes drug called dapagliflozin (also used for heart failure) can help people recover better after a recent heart attack. It's for adults who are already on standard blood thinners and have had a heart attack in the past week.
São Paulo, São PauloAges 18 years+ - NCT07187570RecruitingPhase 3
Dapagliflozin to prevent atrial fibrillation recurrence after cardioversion
This trial tests if the diabetes drug dapagliflozin can lower the chance of atrial fibrillation (an irregular heartbeat) coming back after a procedure called electrical cardioversion, which uses a shock to restore a normal heart rhythm. If you have AF and are scheduled for cardioversion, you may be able to join.
LinköpingAges 55 years+ - NCT07193069Recruiting
Metformin overdose in the ICU – signs and dapagliflozin effects
This study looks at patients who are in the ICU after taking too much metformin (a diabetes drug), sometimes along with another drug called dapagliflozin (Farxiga). The goal is to understand how overdose affects the body and what signs doctors should watch for.
Saint-Denis, FranceAges 18 years+
What Dapagliflozin is being studied for
Conditions with recruiting Dapagliflozin studies.
Common questions
- Are there clinical trials studying Dapagliflozin?
- Yes. Clin2 currently lists 85 recruiting studies that include Dapagliflozin, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Dapagliflozin trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Dapagliflozin an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Dapagliflozin or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.